model421

model421

BNTX close to cash level. Finishing C of (2)? Covid vaccination starts H2. Still interest in mRNA technologies from major players : GSK 1.5 bil deal with CVAC.

model421 Updated 

Both MRNA and BNTX reversed on Friday Engulfing day with decent volume ( and shorts squeeze). The selling was based on playing with the PFE news which effectively was a real no news ( no change in guidance 23 and 24 nobody knows ). In the meantime wastewater traces and hospitalisations for respiratory issues are on the rise worldwide. Cancer vaccines are moving...

model421

Following last ER, I was impressed by BNTX capacity to flex its costs i.e business model (notably vs MRNA) to keep being profitable. Now 17 Bil. in cash. Also believe it was conservative on its modified 2023 guidance compared with PFE ( one is wrong imo). So i believe it is still a cheap stock trading around 30 net of cash (back to before Covid). It filled the...

model421 Updated 

Back to MRNA. Big misunderstanding or lack of homework by the market. US market is only 1/3 if sales. Clients are governments worldwide that order guaranteed doses as insurances. Some contracts APA are for 10 years ( even SAAS are not priced on 10 years visibility ). Last but not least. The price for a 1 dosis ( now packaged in a 1 shot syringe) is not anymore...

model421 Updated 

Doji (W) on both stocks Fundamentals are terrific: Forward cash and equivalents make those stocks nearly free ( pipeline, production capacity, distribution networks priced at 0) : - most contracts for 22 are already signed and/or partly cashed in (US still negotiating for MRNA), - contracts signing for 23 has started as well as governments have to be ready (...

model421 Updated 

I like Zoom fundamentals. Global leaders. Great product. Excellent management. Huge users base that will be leveraged with more added value services. Huge scalability with long term visibility. But. Back to today. So we might break the neckline soon. 155 min target.